Bold claim: research groups say NIH’s plan to cap publisher fees misreads who actually controls publication costs—and it could backfire on researchers who rely on robust journals. And this is the part most people miss: the costs are largely determined by publishers, not by individual labs or even universities, making any cap feel like a blunt instrument rather than a targeted fix.
The National Institutes of Health (NIH) invited public input earlier this year on proposals to limit how researchers can spend grant money to cover journal publication charges. Earlier this month, NIH released the feedback: many major research advocacy groups and other stakeholders argue the ideas are misguided.
A joint statement from the Association of American Medical Colleges, the Association of Public and Land-grant Universities, the Association of American Universities (AAU), and COGR urged NIH to pursue approaches that acknowledge the real drivers of publication costs. They described APCs (article processing charges) as controlled entirely by publishers, not by the institutions or investigators who fund the research.
The AAU comprises leading research institutions, while COGR advocates for researchers and universities at the federal level. The four organizations criticized the proposed APC caps as arbitrary and asked NIH to consider waivers and give universities at least a year to implement any changes and negotiate with publishers.
Meanwhile, NIH gathered more than 900 comments from researchers, associations, publishers, universities, and others during the public-comment window from July 30 to September 15. Coverage by Science highlighted the volume and variety of responses. If enacted, the changes could push the multi-billion-dollar for-profit publishing industry to lower its fees.
The publishing landscape is dominated by a small set of firms that benefit from significant unpaid labor—scholars who perform peer review and authors who, themselves, aren’t paid by publishers but are funded by NIH and other grants.
One NIH proposal was to stop funding publication costs entirely. Another option would cap publication spending at 0.8 percent of direct costs over a grant’s duration or $20,000, whichever is greater.
The four groups argue this still underestimates the true costs researchers face, especially since NIH began mandating open-access publication for funded work this year, eliminating the year-long embargo. Open-access journals often charge higher APCs to cover this model. For context, Nature charges about $12,690 for open-access publication.
They note that the average NIH award last year was roughly $620,000, with about seven publications per award. With APCs near $4,000 on average for journals where NIH-funded work appears, researchers end up spending around $28,000 on APCs across a grant—roughly 4.3 percent of the award, not 0.8 percent.
A key concern is equity: capping APCs could disadvantage less-wealthy institutions and early-career researchers. The fear is researchers might publish in cheaper, lower-impact journals, or even in journals that bypass peer review, which would be especially risky for biomedical and health research.
The American Psychological Association echoed this worry, warning that publishers could shift toward higher volume with looser review, and that caps might drive concentration among large commercial publishers able to absorb lower APCs through broad read-and-publish deals. The APA also noted that established researchers with access to other funding could continue to publish in more expensive journals, widening disparities.
Another major concern from the Big Ten Academic Alliance’s research libraries—responsible for roughly 15 percent of U.S. research publications—was that none of the proposed options would truly achieve the aims. APCs, they argue, reflect what the market will bear, not inherent costs, and limiting payments could push costs elsewhere in the research system or set a higher floor for APCs overall.
They warned that price caps could incentivize publishers to boost article volume by relaxing editorial standards, and stressed the need for transparent data to explain true publishing costs before adjusting fees.
An NIH spokesperson framed the process as an ongoing, careful review of public input. They emphasized that the agency remains in an active evaluation and development phase and is not yet prepared to name a preferred option or timeline for implementation.
If you’re following the debate, the core tension is clear: how to curb what many see as excessive publishing costs without impeding access to high-quality, rigorous peer review. The discussions also raise broader questions about funding models, journal consolidation, and how best to support early-career researchers and institutions with fewer resources. Do you think caps are the right lever, or could there be more targeted reforms that align costs with actual value and quality? Share your thoughts in the comments.
